Axsome Therapeutics Reports Fourth Quarter and Full Year

Feb 27, 2023 · Research and development (R&D) expenses were $14.7 million and $57.9 million for the fourth quarter and full year of 2022 respectively, compared to $13.8 million and $58.1 …

$14
OFF

Axsome Therapeutics Reports Fourth Quarter And Full Year

2 weeks from now

Feb 27, 2023 · Research and development (R&D) expenses were $14.7 million and $57.9 million for the fourth quarter and full year of 2022 respectively, compared to $13.8 million and $58.1 …

globenewswire.com

$19
OFF

Axsome Therapeutics Reports Fourth Quarter And Full Year 2022 …

2 weeks from now

Feb 27, 2023 · Net sales of Sunosi to Axsome were $19.2 million and $44.8 million for the fourth quarter and full year of 2022 respectively. Axsome began selling Sunosi in the U.S. in May …

yahoo.com

$49
OFF

Axsome Therapeutics Reports Fourth Quarter And Full Year

2 weeks from now

Feb 20, 2024 · Auvelity ® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch. Auvelity was launched on October 19, …

globenewswire.com

$24
OFF

Axsome Therapeutics Reports Fourth Quarter And Full Year 2022 …

2 weeks from now

Feb 27, 2023 · Total fourth quarter net product sales of $24.4 million Auvelity® launched October 19th, with fourth quarter net product sales of $5.2 million Sunosi® fourth quarter net product …

marketscreener.com

$24
OFF

Axsome Therapeutics Reports Fourth Quarter And Full Year 2022 …

2 weeks from now

Total fourth quarter net product sales of $24.4 million. Auvelity ® launched October 19th, with fourth quarter net product sales of $5.2 million. Sunosi ® fourth quarter net pro

researchpool.com

$13
OFF

Axsome Therapeutics Reports Fourth Quarter And Full Year

2 weeks from now

Mar 1, 2022 · Fourth Quarter and Full Year 2021 Financial Results Research and development (R&D) expenses: R&D expenses were $13.8 million for the three months ended December 31, …

globenewswire.com

$24
OFF

Axsome Therapeutics Reports Fourth Quarter And Full Year 2022

2 weeks from now

Feb 27, 2023 · Total fourth quarter net product sales of $24.4 million Auvelity® launched October 19th, with fourth quarter net product sales of $5.2 million Sunosi® fourth quarter net product …

ktla.com

$92
OFF

Axsome Therapeutics Provides Preliminary Fourth Quarter And Full …

2 weeks from now

1 day ago · Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively Sunosi preliminary 4Q and full year 2024 net product revenue of …

yahoo.com

$1.34
OFF

Axsome Therapeutics (AXSM) Earnings Date And Reports 2025

2 weeks from now

In the previous quarter, Axsome Therapeutics (NASDAQ:AXSM) reported ($1.34) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.38) by $0.04. ... The conference …

marketbeat.com

5%
OFF

Axsome (AXSM) Moves 11.5% Higher: Will This Strength Last?

2 weeks from now

Axsome Therapeutics (AXSM) shares ended the last trading session 11.5% higher at $89.27. ... Auvelity and Sunosi, for the fourth quarter and full year 2024. Auvelity sales in the fourth …

nasdaq.com

3%
OFF

Axsome Therapeutics (NASDAQ:AXSM) Stock Price Up 5.3% On

2 weeks from now

2 days ago · Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same quarter last year, the company posted ($1.32) earnings …

marketbeat.com

4%
OFF

Axsome Therapeutics Expects Q4 And FY24 Revenue Marginally …

2 weeks from now

Sunosi net product revenue is expected to be approximately $25.7 million and $93.8 million for the fourth quarter and full year of 2024, respectively. AXSM +2.4% premarket to $82.0 Source: …

msn.com

$24
OFF

Axsome Therapeutics Reports Fourth Quarter And Full Year 2022 …

2 weeks from now

Total fourth quarter net product sales of $24.4 million Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update, by …

ceo.ca

$25
OFF

Axsome Therapeutics Provides Preliminary Fourth Quarter And

2 weeks from now

1 day ago · Sunosi® net product revenue is expected to be approximately $25.7 million and $93.8 million for the fourth quarter and full year of 2024, respectively. ... About Axsome …

globenewswire.com

$24
OFF

Axsome Therapeutics Reports Fourth Quarter And Full Year 2022 …

2 weeks from now

Feb 27, 2023 · Total fourth quarter net product sales of $24.4 million Auvelity® launched October 19th, with fourth quarter net product sales of $5.2 million Sunosi® fourth quarter net product …

whnt.com

$24
OFF

Axsome Therapeutics Reports Fourth Quarter And Full Year 2022 …

2 weeks from now

Feb 27, 2023 · Axsome Therapeutics reported fourth quarter 2022 net product sales of $24.4 million, with Auvelity generating $5.2 million and Sunosi $19.2 million. The company launched …

stocktitan.net

FAQs about Axsome Therapeutics Reports Fourth Quarter and Full Year Coupon?

When is Axsome Therapeutics's next earnings report?

Axsome Therapeutics has confirmed that its next quarterly earnings report will be published on Monday, August 7th, 2023. Axsome Therapeutics will be holding an earnings conference call on Monday, August 7th at 8:00 AM Eastern. Interested parties can register for or listen to the call.. When is Axsome Therapeutics's earnings date? ...

How much money does Axsome Therapeutics make a year?

Axsome Therapeutics (NASDAQ:AXSM) has a recorded annual revenue of $50.04 million. How much profit does Axsome Therapeutics generate each year? Axsome Therapeutics (NASDAQ:AXSM) has a recorded net income of -$187.13 million. AXSM has generated -$3.80 earnings per share over the last four quarters. ...

Who is Axsome Therapeutics?

Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. ...

What is the recording of the Axsome Therapeutics conference call?

A recording of the conference call will be available on the Company’s website for approximately 30 days following the live event. Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options. ...

When will Axsome start a Phase 2/3 study?

Smoking Cessation: Axsome plans to proceed to a pivotal Phase 2/3 trial in this indication. The Company anticipates initiation of this study in the fourth quarter of 2023. AXS-07 (MoSEIC™ meloxicam-rizatriptan) is Axsome’s novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine for the acute treatment of migraine. ...

Can Axsome transform the treatment landscape for depression?

“The past year was a landmark for Axsome, which saw us bring our first fully in-house end-to-end developed drug to market, potentially transforming the treatment landscape for depression and providing the potential to improve the lives of millions of patients and their loved ones,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. ...